nitazoxanide + peginterferon alfa-2a

**Nitazoxanide + peginterferon alfa-2a** is a combination therapy consisting of nitazoxanide, a broad-spectrum antiviral and antiparasitic agent, and peginterferon alfa-2a, a pegylated recombinant human interferon. The combination has been investigated as a treatment for chronic hepatitis C, particularly in combination with ribavirin in patients who failed to respond to standard therapy with peginterferon and ribavirin[1][3][5]. - **Nitazoxanide** acts by interfering with host-regulated pathways essential for viral replication, enhancing the immune response, and has shown direct and additive antiviral effects with interferon. - **Peginterferon alfa-2a** stimulates the innate antiviral immune response by binding to human type 1 interferon receptors, activating the JAK/STAT pathway, and inducing many interferon-stimulated genes that inhibit viral replication[2]. Clinical studies indicate the triple combination (nitazoxanide, peginterferon alfa-2a, and ribavirin) can increase rates of sustained virological response compared to standard dual therapy, without a marked increase in adverse events[3][5].